Blood biomarker modulation with dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies

Ann Marie Egloff,T. M. Feinstein,Sonali Joyce,Lori A. Kelly,Monica C. Panelli,T. Yang,Jill M. Siegfried,Jennifer R. Grandis,Athanassios Argiris

Blood biomarker modulation with dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies

2016

Ann Marie Egloff
T. M. Feinstein
Sonali Joyce
Lori A. Kelly
Monica C. Panelli
T. Yang
Jill M. Siegfried
Jennifer R. Grandis
Athanassios Argiris

6034 Background: Src is implicated in the resistance to epidermal growth factor receptor (EGFR) inhibitors. We studied biomarkers in the context of a phase I clinical trial of D, a small molecule i...

Keywords:

Phases of clinical research
Medicine
Epidermal growth factor receptor
Small molecule
Pathology
Biomarker (medicine)
Dasatinib
Proto-oncogene tyrosine-protein kinase Src
Cetuximab
Cancer research
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations